Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Amylyx pharmaceuticals inc org | Vintage Vibes

Controversial ALS drug from Amylyx gets rare second FDA meeting

Amylyx Pharmaceuticals Inc.’s controversial treatment for amyotrophic lateral sclerosis won the support of a panel of U.S. regulatory advisers, putting the product on track for likely clearance.

Tribune News Service · Sep 7, 2022

Here's How Citi Views Amylyx Pharma

Citi Research has raised the price target on Amylyx Pharmaceuticals Inc's (NASDAQ:AMLX) to $33 from $32, with a Buy rating. It says the small market opportunity for the newly approved amyotrophic lateral sclerosis (ALS) drug in Canada (~$100 million peak) bodes well for ongoing FDA review. Availability in Canada and using ALSFRS-R data as the primary basis…

Benzinga · Jun 14, 2022

Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September

The Canadian government has given its approval to AMX0035, a new drug from Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc.

Benzinga · Jun 13, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Stealth BioTherapeutics Shares Are Surging Today?

Stealth BioTherapeutics Corp (NASDAQ:MITO) presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology. TDP-43 pathology plays a significant role in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The data were presented at the Keystone Neurodegeneration Symposium. A Phase 1 study to evaluate the safety and tolerability…

Benzinga · Jun 8, 2022

Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today

Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035.

Benzinga · Jun 3, 2022

Amylyx Shares Plummet On Skeptical FDA Adcomm Docs On ALS Drug

The FDA released its briefing documents for the advisory committee to discuss Amylyx Pharmaceuticals Inc's (NASDAQ:AMLX) sodium phenylbutyrate/taurursodiol (AMX0035) powder for amyotrophic lateral sclerosis (ALS). Agency statisticians called into question the Company's efficacy and survival analyses, raising concern that the modest survival benefit seen may potentially be due to underlying disease heterogeneity rather than…

Benzinga · Mar 28, 2022

FDA Sets Up Adcomm To Review Amylyx's ALS Drug Next Month

The FDA's Peripheral and Central Nervous System Drugs Advisory Committee will review Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) marketing application for AMX0035 (sodium phenylbutyrate [PB] and taurursodiol)

Benzinga · Feb 17, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Organisations

Amylyx Pharmaceuticals

11 stories

MITO

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Amyotrophic lateral sclerosis

35 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.